【摘要】 目的　观察胰岛素增敏剂罗格列酮合用二甲双胍治疗 2型糖尿病 (2 DM)的临床疗效和安全性。方法　应用治疗前后自身对照的方法 ,37例经双胍类以及磺脲类加双胍类治疗 ,血糖控制不佳的 2 DM患者 ,改用罗格列酮 4mg口服 ,每日 1次 ,同时给二甲双胍 2 5 0～ 5 0 0mg口服 ,每日 3次 ,观察治疗前和治疗 12周后空腹血糖以及餐后 2h的血糖 (FBG、PBG)、胰岛素 (FINS、PINS)、糖化血红蛋白(HbAlc)以及胰岛素敏感指数 (ISI)和胰岛素抵抗指数(IRI) ,监测血脂 ,肝肾功能和血常规等。结果　治疗 12周后与治疗前相比较 ,FBG、PBG、FINS、PINS下降 ,ISI增加 ,IRI降低 ,差异有显著性 ;HbAlc和血脂变化不大 ,副作用轻微 ,肝肾功能无损害。结论　罗格列酮明显改善外周组织对胰岛素的敏感性 ,加二甲双胍合用治疗 2 DM降血糖疗效确切 ,临床应用安全性好更多还原

【Abstract】 Objective To investigate the effects and safety of ro siglitazone plus metformin in treating type 2 diabetes mellitus (2 DM). Methods 37 type 2 diabetic patients with poor blood glucose control treated by metformin or suplus metformin were selected and administered with rosiglitazone (4mg, qd) and metformin (250～500 mg, tid) Fasting blood glucose(FBG), postprandial blood glucose(PBG), fasting insulin(FINS), postprandial insulin(PINS), HbAlc, insulin sensitive index(ISI), insulin resistance index(IRI), lipid and liver and renal functions was observed before and 12 weeks after treatment Results Compared with pre treatment values, FBG, PBG, FINS, PINS and IRI decreased but IAI increased significantly The changes in HbAlc and lipid were of no statistical significance Side effects of the treatment were slight and no liver and renal function impairment was observed. Conclusion Rosiglitazone plus metformin not only can reduce hyper glycemia and enhance peripheral tissue sensitivity to insulin but also is safety in clinical treatment更多还原